Jin Fu

Title: Innovations of Jin Fu in Oncolytic Adenoviruses

Introduction

Jin Fu is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of oncolytic adenoviruses for cancer treatment. His innovative work focuses on creating pharmaceutical compositions that can effectively target tumors and cancers.

Latest Patents

Jin Fu holds a patent for an isolated recombinant oncolytic adenovirus, which is designed for use in pharmaceutical compositions aimed at treating tumors and cancers. The patent details a selectively replicating oncolytic adenovirus whose genome is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. This innovative approach allows the virus to replicate more efficiently in tumor cells compared to normal primary cells. The expressed shPDL1 significantly reduces the level of PDL1 protein in tumor cells, enhancing the oncolytic killing effect of the virus and stimulating an anti-tumor immune response.

Career Highlights

Jin Fu is associated with Hangzhou Converd Co., Ltd., where he continues to advance his research in oncolytic viruses. His work has the potential to revolutionize cancer treatment by combining viral therapy with immunotherapy, creating a synergistic effect that could improve patient outcomes.

Collaborations

Jin Fu collaborates with notable colleagues, including Jipo Sheng and Ronghua Zhao, who contribute to his research efforts and innovations in the field.

Conclusion

Jin Fu's contributions to the development of oncolytic adenoviruses represent a significant advancement in cancer treatment. His innovative approach and dedication to research continue to pave the way for new therapeutic options in oncology.